NO973884L - Aminosyrepreparater og anvendelse derav for klinisk ernæring - Google Patents

Aminosyrepreparater og anvendelse derav for klinisk ernæring

Info

Publication number
NO973884L
NO973884L NO973884A NO973884A NO973884L NO 973884 L NO973884 L NO 973884L NO 973884 A NO973884 A NO 973884A NO 973884 A NO973884 A NO 973884A NO 973884 L NO973884 L NO 973884L
Authority
NO
Norway
Prior art keywords
tnf
amino acid
levels
macrophage
reduction
Prior art date
Application number
NO973884A
Other languages
English (en)
Norwegian (no)
Other versions
NO973884D0 (no
Inventor
Heinz Schneider
Ronald G Thurman
Original Assignee
Novartis Nutrition Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08392694 external-priority patent/US5656608B1/en
Priority claimed from GBGB9512100.0A external-priority patent/GB9512100D0/en
Application filed by Novartis Nutrition Ag filed Critical Novartis Nutrition Ag
Publication of NO973884D0 publication Critical patent/NO973884D0/no
Publication of NO973884L publication Critical patent/NO973884L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pediatric Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO973884A 1995-02-23 1997-08-22 Aminosyrepreparater og anvendelse derav for klinisk ernæring NO973884L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08392694 US5656608B1 (en) 1995-02-23 1995-02-23 Amino acid compositions and methods of treatment using same
GBGB9512100.0A GB9512100D0 (en) 1995-06-14 1995-06-14 Improvements in or relating to organic compounds
PCT/EP1996/000739 WO1996025861A1 (en) 1995-02-23 1996-02-22 Amino acid compositions and use thereof in clinical nutrition

Publications (2)

Publication Number Publication Date
NO973884D0 NO973884D0 (no) 1997-08-22
NO973884L true NO973884L (no) 1997-10-17

Family

ID=26307213

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973884A NO973884L (no) 1995-02-23 1997-08-22 Aminosyrepreparater og anvendelse derav for klinisk ernæring

Country Status (18)

Country Link
EP (1) EP0810829B1 (de)
JP (1) JPH11501301A (de)
KR (1) KR19980702436A (de)
CN (1) CN1175887A (de)
AT (1) ATE191615T1 (de)
AU (1) AU710527B2 (de)
BR (1) BR9607336A (de)
CA (1) CA2210499A1 (de)
CZ (1) CZ266797A3 (de)
DE (1) DE69607750T2 (de)
DK (1) DK0810829T3 (de)
ES (1) ES2145997T3 (de)
FI (1) FI972744L (de)
HU (1) HUP9800049A3 (de)
NO (1) NO973884L (de)
PL (1) PL182205B1 (de)
PT (1) PT810829E (de)
WO (1) WO1996025861A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JP2000515874A (ja) * 1996-07-30 2000-11-28 ノバルテイス・ニユートリシヨン・アクチエンゲゼルシヤフト アミノ酸組成物、ならびに腫瘍の成長および転移の処置におけるその使用
US6096785A (en) * 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
GB9701674D0 (en) * 1997-01-28 1997-03-19 Novartis Nutrition Ag Use of organic compounds
ES2221095T3 (es) * 1997-06-05 2004-12-16 Novartis Nutrition Ag Glicina para prevencion o tratamiento del rechazo de transplantes.
KR20010022323A (ko) * 1997-07-28 2001-03-15 고바야시 순이치 중추신경세포의 보호 및 생존촉진제
US6143786A (en) * 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
DE10257360A1 (de) * 2002-12-09 2004-07-08 Fresenius Kabi Deutschland Gmbh Gastro-intestinal verabreichbare Formulierung und deren Verwendung
US20060280776A1 (en) * 2003-09-02 2006-12-14 Masafumi Koide Diet food
EP1591118A1 (de) 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Verwendung von Melatonin zur Vorbeugung von postoperativen Komplikationen
KR100555904B1 (ko) * 2004-05-19 2006-03-03 주식회사 오스코텍 큰느타리버섯과 오가피의 혼합 생약재 추출물 및 이를유효성분으로 하는 골다공증 예방 및 치료용 조성물
CN101472612B (zh) * 2006-06-14 2011-06-08 纽崔西亚公司 包含甘氨酸和乳铁蛋白的抗炎组合物及其应用
CA2709660C (en) 2008-01-04 2018-06-05 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US20100179089A1 (en) * 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
ES2517340T3 (es) * 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
KR101213825B1 (ko) * 2010-07-16 2012-12-18 서울대학교산학협력단 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물
JP6000253B2 (ja) 2010-09-24 2016-09-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 胃腸機能を改善するための材料および方法
MX361647B (es) 2013-03-11 2018-12-13 Univ Florida Materiales y métodos para mejorar la función pulmonar y para la prevención y/o tratamiento de complicaciones pulmonares inducidas por radiación.
EP3459540A1 (de) 2014-11-24 2019-03-27 Entrinsic Health Solutions, Inc. Aminosäurezusammensetzungen zur behandlung der symptome einer krankheit
US10500179B2 (en) 2015-10-02 2019-12-10 N. V. Nutricia Glycine for use in tolerance induction in allergic patients
FR3041882B1 (fr) * 2015-10-06 2019-04-12 Universite D'angers Preparation pharmaceutique pour le traitement preventif de lesions d'ischenie reperfusion
EP3522882A4 (de) 2016-10-04 2020-06-24 The University of Florida Research Foundation Incorporated Aminosäurezusammensetzungen und verwendungen davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591893B1 (fr) * 1985-12-19 1988-11-10 Centre Nat Rech Scient Compositions nutritionnelles carencees en methionine destinees a inhiber le developpement et la dissemination des tumeurs malignes chez les mammiferes
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
AU664210B2 (en) * 1991-09-27 1995-11-09 Board Of Regents, The University Of Texas System Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease

Also Published As

Publication number Publication date
WO1996025861A1 (en) 1996-08-29
CZ266797A3 (cs) 1998-03-18
CA2210499A1 (en) 1996-08-29
EP0810829B1 (de) 2000-04-12
NO973884D0 (no) 1997-08-22
ATE191615T1 (de) 2000-04-15
HUP9800049A3 (en) 1999-01-28
HUP9800049A2 (hu) 1998-05-28
DE69607750T2 (de) 2000-08-31
FI972744A7 (fi) 1997-08-22
PL182205B1 (pl) 2001-11-30
EP0810829A1 (de) 1997-12-10
DK0810829T3 (da) 2000-08-28
FI972744L (fi) 1997-08-22
JPH11501301A (ja) 1999-02-02
PL321238A1 (en) 1997-11-24
ES2145997T3 (es) 2000-07-16
CN1175887A (zh) 1998-03-11
FI972744A0 (fi) 1997-06-25
PT810829E (pt) 2000-08-31
MX9706140A (es) 1997-11-29
AU4879596A (en) 1996-09-11
DE69607750D1 (de) 2000-05-18
AU710527B2 (en) 1999-09-23
BR9607336A (pt) 1997-11-25
KR19980702436A (ko) 1998-07-15

Similar Documents

Publication Publication Date Title
FI972744A0 (fi) Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa
Lips et al. Determinants of vitamin D status in patients with hip fracture and in elderly control subjects
Schjoldager et al. Oxyntomodulin from distal gut: role in regulation of gastric and pancreatic functions
BOIVIN et al. Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans
CA2410880A1 (en) 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
CA2229279A1 (en) Nutritional and/or dietary composition and method of using the same
NZ272610A (en) The manufacture of dispersible tablets containing fluoxetine by direct compression
Pusztai et al. Lipid accumulation in obese Zucker rats is reduced by inclusion of raw kidney bean (Phaseolus vulgaris) in the diet
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
JP2001524119A (ja) 増加した骨吸収の治療のための植物抽出物
EP1263448B1 (de) Maca und geweih zur steigerung des testosteronspiegels
EP0981352B8 (de) Verwendung von Aplidine zur Behandlung von kardiovaskulären Erkrankungen
CN109862906A (zh) 用于口服的活性剂的制剂
NO994431L (no) Ny formulering
McLaren Nutrition and wound healing
MXPA02012064A (es) Complejos de farmaco macromoleculares y composiciones que los contienen.
JPH0667832B2 (ja) 腫瘍性疾患の治療に用いるプログルミド含有医薬組成物
Bloomgarden International Diabetes Federation Meeting, 1997: Type 2 diabetes: its prevalence, causes, and treatment
Wildburger et al. Comparison of the values of basic fibroblast growth factor determined by an immunoassay in the sera of patients with traumatic brain injury and enhanced osteogenesis and the effects of the same sera on the fibroblast growth in vitro
Konturek et al. Effect of thyrotropin-releasing hormone on gastro-intestinal secretions in dogs
Vidon et al. Does lansoprazole influence postprandial digestive function?
D’Souza et al. Calcium metabolism in pancreatic disease
HU194736B (en) Improved process for production of antiinflammable preparative
Wang et al. Effects of arginine-devoid diets in chronically uremic rats
Spannagel et al. Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application